AR127271A1 - BISPECIFIC ANTIBODIES THAT BIND SPECIFICALLY TO CD47 AND CD20, AND USES THEREOF - Google Patents
BISPECIFIC ANTIBODIES THAT BIND SPECIFICALLY TO CD47 AND CD20, AND USES THEREOFInfo
- Publication number
- AR127271A1 AR127271A1 ARP220102708A ARP220102708A AR127271A1 AR 127271 A1 AR127271 A1 AR 127271A1 AR P220102708 A ARP220102708 A AR P220102708A AR P220102708 A ARP220102708 A AR P220102708A AR 127271 A1 AR127271 A1 AR 127271A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- amino acid
- acid sequence
- set forth
- specifically binding
- Prior art date
Links
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 title abstract 5
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 title abstract 5
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 title abstract 4
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 title abstract 4
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 6
- 238000000034 method Methods 0.000 abstract 5
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229940127121 immunoconjugate Drugs 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La invención se relaciona con anticuerpos biespecíficos novedosos, que comprenden al menos un dominio de unión capaz de unirse específicamente a CD47 y al menos un dominio de unión capaz de unirse específicamente a CD20. La invención además se relaciona con métodos para producir estos anticuerpos biespecíficos y con métodos para usar los mismos. Reivindicación 1: El anticuerpo biespecífico comprende (a) al menos un dominio de unión a antígeno capaz de unirse específicamente a CD47, y (b) y al menos un dominio de unión a antígeno capaz de unirse específicamente a CD20, en donde el dominio de unión a antígeno capaz de unirse específicamente a CD47 comprende una VH y una VL, en donde la VH comprende HCDR1 que comprende o consiste en la secuencia de aminoácidos como se establece en SEQ ID Nº 11, HCDR2 que comprende o consiste en la secuencia de aminoácidos como se establece en SEQ ID Nº 12, y HCDR3 que comprende o consiste en la secuencia de aminoácidos como se establece en SEQ ID Nº 13 o 17 o 21, y la VL comprende LCDR1 que comprende o consiste en la secuencia de aminoácidos como se establece en SEQ ID Nº 14, LCDR2 que comprende o consiste en la secuencia de aminoácidos como se establece en SEQ ID Nº 15 o 18 o 22, y LCDR3 que comprende o consiste en la secuencia de aminoácidos como se establece en SEQ ID Nº 16. Reivindicación 37: Un método para tratar o prevenir una enfermedad o afección en un sujeto, que comprende administrar a un individuo una cantidad eficaz del anticuerpo biespecífico de una cualquiera de las reivindicaciones 1 - 31, el ácido nucleico de la reivindicación 32, el vector de la reivindicación 33, la célula huésped de la reivindicación 34, o el inmunoconjugado de la reivindicación 35, o la composición farmacéutica de la reivindicación 36. Reivindicación 38: El método de la reivindicación 37, en donde la enfermedad o afección está relacionada con CD47 y/o relacionada con CD20. Reivindicación 39: El método de una cualquiera de las reivindicaciones 37 - 38, en donde la enfermedad o afección es cáncer.The invention relates to novel bispecific antibodies, comprising at least one binding domain capable of specifically binding to CD47 and at least one binding domain capable of specifically binding to CD20. The invention further relates to methods of producing these bispecific antibodies and to methods of using the same. Claim 1: The bispecific antibody comprises (a) at least one antigen binding domain capable of specifically binding to CD47, and (b) and at least one antigen binding domain capable of specifically binding to CD20, wherein the antigen binding capable of specifically binding to CD47 comprises a VH and a VL, wherein the VH comprises HCDR1 comprising or consisting of the amino acid sequence as set forth in SEQ ID NO: 11, HCDR2 comprising or consisting of the amino acid sequence as set forth in SEQ ID NO: 12, and HCDR3 comprising or consisting of the amino acid sequence as set forth in SEQ ID NO: 13 or 17 or 21, and VL comprising LCDR1 comprising or consisting of the amino acid sequence as set forth in SEQ ID NO: 14, LCDR2 comprising or consisting of the amino acid sequence as set forth in SEQ ID NO: 15 or 18 or 22, and LCDR3 comprising or consisting of the amino acid sequence as set forth in SEQ ID NO: 16. Claim 37: A method of treating or preventing a disease or condition in a subject, comprising administering to an individual an effective amount of the bispecific antibody of any one of claims 1 - 31, the nucleic acid of claim 32, the vector of the claim 33, the host cell of claim 34, or the immunoconjugate of claim 35, or the pharmaceutical composition of claim 36. Claim 38: The method of claim 37, wherein the disease or condition is related to CD47 and/ or related to CD20. Claim 39: The method of any one of claims 37-38, wherein the disease or condition is cancer.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021122855 | 2021-10-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR127271A1 true AR127271A1 (en) | 2024-01-03 |
Family
ID=85803937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220102708A AR127271A1 (en) | 2021-10-09 | 2022-10-06 | BISPECIFIC ANTIBODIES THAT BIND SPECIFICALLY TO CD47 AND CD20, AND USES THEREOF |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR127271A1 (en) |
| TW (1) | TW202325735A (en) |
| WO (1) | WO2023056969A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR121805A1 (en) * | 2020-04-10 | 2022-07-13 | Hutchison Medipharma Ltd | ANTI-CD47 ANTIBODY AND USES OF THE SAME |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016378573A1 (en) * | 2015-12-22 | 2018-07-19 | Regeneron Pharmaceuticals, Inc. | Bispecific anti-CD20/anti-CD3 antibodies to treat acute lymphoblastic leukemia |
| WO2018223004A1 (en) * | 2017-06-01 | 2018-12-06 | Xencor, Inc. | Bispecific antibodies that bind cd20 and cd3 |
| CN110885376B (en) * | 2018-09-11 | 2020-10-09 | 上海洛启生物医药技术有限公司 | anti-CD 47/CD20 bispecific antibodies and uses thereof |
| CN110066336B (en) * | 2019-05-12 | 2021-11-09 | 杭州科兴生物科技有限公司 | anti-CD 47 monoclonal antibody, fragment and medical application thereof |
| CN111423515A (en) * | 2020-03-23 | 2020-07-17 | 倍而达药业（苏州）有限公司 | CD20/CD47 bispecific antibody and application |
-
2022
- 2022-10-06 AR ARP220102708A patent/AR127271A1/en unknown
- 2022-10-07 TW TW111138265A patent/TW202325735A/en unknown
- 2022-10-09 WO PCT/CN2022/124082 patent/WO2023056969A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202325735A (en) | 2023-07-01 |
| WO2023056969A1 (en) | 2023-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR110017A1 (en) | PD-1 ANTIBODIES AND USES OF THESE | |
| PE20210180A1 (en) | ANTI-CD33 ANTIBODIES, ANTI-CD33 / ANTI-CD3 BISPECIFIC ANTIBODIES AND USES OF THEM | |
| AR100573A1 (en) | ANTIBODIES ANTI-IL-17, A METHOD FOR PRODUCING AND USING THEM | |
| PE20200294A1 (en) | ANTIBODIES THAT SPECIFICALLY BIND PD-1 AND METHODS OF USE | |
| AR126019A1 (en) | ANTIBODIES AGAINST ENTPD2, COMBINATION THERAPIES AND METHODS OF USE OF ANTIBODIES AND COMBINATION THERAPIES | |
| AR106184A1 (en) | PD-1 BINDING PROTEINS AND THEIR METHODS OF USE | |
| AR103868A1 (en) | ANTI-CD47 ANTIBODIES AS THERAPEUTIC AGENTS | |
| PE20110797A1 (en) | ANTI MN ANTIBODIES | |
| CL2010001544A1 (en) | Humanized monoclonal antibody or binding fragment that binds and neutralizes the human vascular endothelial growth factor (hvegf); composition that includes it; nucleic acid coding; vector; host cell; its use to treat or prevent a disease mediated by vegf; and hybridoma. | |
| AR104906A1 (en) | ANTIBODIES DIRECTED TO THE BONE MORPHOGENETIC PROTEIN 9 (BMP9) AND METHODS FROM THESE | |
| RU2017114968A (en) | BINDING MOLECULES, AND EXACTLY ANTIBODIES, ABLE TO CONTACT L1CAM (CD171) | |
| AR123480A1 (en) | THERAPEUTIC BINDING MOLECULES | |
| RU2014127287A (en) | ANTIBODIES USED FOR PASSIVE VACCINATION AGAINST INFLUENZA | |
| CO2018001256A2 (en) | Anti-cd154 antibodies and methods to produce them | |
| HRP20192038T1 (en) | Anti-epidermal growth factor receptor (egfr) antibodies | |
| AR070821A1 (en) | ANTI-TYRP1 ANTIBODY (HUMAN ANTITIROXIN) | |
| PE20201255A1 (en) | CD123 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES SPECIFIC TO CD123 AND USES THEREOF | |
| AR110967A1 (en) | MIMETIC ANTIBODIES FGF21 AND ITS USE | |
| AR105978A1 (en) | THERMAL STROMAL LYMPHOPYETIN BINDING MOLECULES (TSLP) AND METHODS OF USE OF THE MOLECULES | |
| PE20231080A1 (en) | ANTIBODIES THAT BIND CD3 AND CD19 | |
| HRP20220088T1 (en) | Fixaxfx bispecific antibody with common light chain | |
| AR123912A2 (en) | ANTIBODIES THAT BIND TGF-α AND EPIREGULIN | |
| PE20240363A1 (en) | ANTI-CCR8 ANTIBODIES AND USES THEREOF | |
| RU2020100073A (en) | NEUTRALIZING ANTIBODIES TO INFLUENZA B VIRUS AND WAYS OF THEIR APPLICATION | |
| AR127271A1 (en) | BISPECIFIC ANTIBODIES THAT BIND SPECIFICALLY TO CD47 AND CD20, AND USES THEREOF |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |